4 / 51
Page 52
Journal of Clinical Immunology and Allergy
ISSN: 2471-304X
E u r o p e a n C o n g r e s s o n
Vaccines & Vaccination
and Gynecologic Oncology
Vaccines & Vaccination and Gynecologic Oncology 2018
O c t o b e r 2 6 - 2 7 , 2 0 1 8
B u d a p e s t , H u n g a r y
Survival outcomes of adjuvant therapy in
uterine-confined endometrial cancer which
has serous papillary and clear cell histology:
radiotherapy versus chemotherapy
Miseon Kim
1
, Byung Su Kwon
2
, Ha Kyun Chang
3
, Seungmee
Lee
4
, Suk-Joon Chang
5
, Jin Young Choi
6
, Sang-Yoon Park
3
,
Maria Lee
7
, Hee-Sug Ryu
5
and Yong Beom Kim
8
1
CHA Gangnam Medical Center, CHA University School of Medicine, Republic of Korea
2
Pusan National University Hospital, Republic of Korea
3
Center for Uterine Cancer-National Cancer Center, Goyang, Republic of Korea
4
Keimyung University, Republic of Korea
5
Ajou University, Republic of Korea
6
Chungbuk National University Hospital, Republic of Korea
7
Seoul National University, Republic of Korea
8
Seoul National University Bundang Hospital, Republic of Korea
Miseon Kim et al., Crit Care Obst & Gyne 2018, Volume: 4
DOI:2471-9803-C1-003
Objective:
To evaluate the survival outcomes of adjuvant therapy in uterine-confined endometrial cancer with serous papillary and clear cell histology
Methods:
Medical records of 80 women who underwent surgical staging including hysterectomy and bilateral salpingo-oophorectomy between Nov’
2004 and Dec’ 2017 were retrospectively reviewed. All study population was pathologically diagnosed as serous papillary and clear cell endometrial
carcinoma confined to uterus after surgery. Survival outcomes were calculated by Kaplan-Meier method and compared using log-rank test between
the women received radiotherapy and chemotherapy.
Results:
54 (67.5%) and 26 (32.5%) womenwere confirmed as serous papillary and clear cell histology after surgery, respectively. Adjuvant therapy was
performed in 59/80 (73.8%) women: 25 of radiotherapy and 34 of chemotherapy. High level of preoperative serum CA-125 (25.1±20.2 vs. 11.5±6.5
IU/mL, p<0.001), open surgery (42 (71.2%) vs. 6 (28.6%), p=0.001), myometrium invasion >1/2 (20 (33.9%) vs. 0, p=0.002) and lymphovascular space
invasion (LVSI (lymphovascular space invasion), 17 (28.8%) vs. 1 (4.8%), p=0.023) were frequent in the women with adjuvant therapy. However,
pathological results including histology type, myometrial invasion ≥1/2 and LVSI were not different between the women received radiotherapy and
chemotherapy. Five-year progression-free survival (78.9 vs. 80.1%, p>0.999) and overall survival (77.5 vs. 87.8%, p=0.373) were also similar in the
two groups. Neither radiotherapy (Hazard ratio (HR) 1.810, 95% confidence interval (CI) 0.297-11.027; p=0.520) nor chemotherapy (HR 1.638, 95% CI
0.288-9.321; p=0.578) was independent associated factor for disease recurrence in multivariate analysis.
Conclusion:
Our findings show that radiotherapy and chemotherapy have similar survival outcomes in uterine-confined endometrial cancer with
serous papillary and clear cell histology. Further study with stratified analysis by myometrial invasion or LVSI was required.
shemme@naver.com miseonkim@chamc.co.kr